SynAct Pharma AB

OM:SYNACT Stock Report

Market Cap: SEK 462.5m

SynAct Pharma Management

Management criteria checks 0/4

SynAct Pharma's CEO is Jeppe Ovlesen, appointed in Mar 2024, has a tenure of less than a year. directly owns 0.033% of the company’s shares, worth SEK154.85K. The average tenure of the management team and the board of directors is 1.6 years and 0.8 years respectively.

Key information

Jeppe Ovlesen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.03%
Management average tenure1.6yrs
Board average tenureless than a year

Recent management updates

Recent updates

We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

Sep 18
We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

Sep 04
Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

Jan 18
Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

Sep 03
Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

Apr 07
SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth

Dec 23
Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth

CEO Compensation Analysis

How has Jeppe Ovlesen's remuneration changed compared to SynAct Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 155m

Jun 30 2024n/an/a

-SEK 166m

Mar 31 2024n/an/a

-SEK 191m

Dec 31 2023n/an/a

-SEK 216m

Sep 30 2023n/an/a

-SEK 156m

Jun 30 2023n/an/a

-SEK 148m

Mar 31 2023n/an/a

-SEK 129m

Dec 31 2022SEK 4mSEK 3m

-SEK 99m

Sep 30 2022n/an/a

-SEK 95m

Jun 30 2022n/an/a

-SEK 89m

Mar 31 2022n/an/a

-SEK 78m

Dec 31 2021SEK 2mSEK 2m

-SEK 69m

Sep 30 2021n/an/a

-SEK 52m

Jun 30 2021n/an/a

-SEK 41m

Mar 31 2021n/an/a

-SEK 35m

Dec 31 2020SEK 2mSEK 2m

-SEK 27m

Sep 30 2020n/an/a

-SEK 29m

Jun 30 2020n/an/a

-SEK 24m

Mar 31 2020n/an/a

-SEK 23m

Dec 31 2019SEK 2mSEK 2m

-SEK 24m

Sep 30 2019n/an/a

-SEK 20m

Jun 30 2019n/an/a

-SEK 23m

Mar 31 2019n/an/a

-SEK 24m

Dec 31 2018SEK 2mSEK 2m

-SEK 23m

Compensation vs Market: Insufficient data to establish whether Jeppe's total compensation is reasonable compared to companies of similar size in the Swedish market.

Compensation vs Earnings: Jeppe's compensation has increased whilst the company is unprofitable.

CEO

Jeppe Ovlesen (62 yo)

less than a year

Tenure

SEK 3,656,000

Compensation

Mr. Jeppe Ovli Ovlesen, EE, MBA, serves CEO & Director of SynAct Pharma AB since March 20, 2024. He serves as Director at Cereno Scientific AB (publ) since November 07, 2023. He served as the Chief Execut...

Leadership Team

NamePositionTenureCompensationOwnership
Jeppe Ovlesen
CEO & Directorless than a yearSEK 3.66m0.033%
SEK 154.9k
Bjorn Westberg
Chief Financial Officer1.6yrsno datano data
Thomas Boesen
Chief Operating Officer4yrsno data0.045%
SEK 208.4k
James Knight
Chief Business Officer3.9yrsno datano data
Kristen Harting
Chief Medical Officerless than a yearno datano data

1.6yrs

Average Tenure

Experienced Management: SYNACT's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jeppe Ovlesen
CEO & Directorless than a yearSEK 3.66m0.033%
SEK 154.9k
Sten Scheibye
Directorless than a yearno datano data
Vibeke Strand
Member of Clinical Advisory Boardless than a yearno datano data
Mauro Perretti
Member of Scientific Advisory Boardno datano datano data
Anders Kronborg
Chairman of Boardless than a yearno datano data
Sten Sorensen
Directorless than a yearno datano data
Ravi Rao
Member of Clinical Advisory Boardless than a yearno datano data
Roy Fleischmann
Member of Clinical Advisory Boardless than a yearno datano data
Mauro Teixeira
Member of Scientific Advisory Boardno datano datano data

0.8yrs

Average Tenure

62yo

Average Age

Experienced Board: SYNACT's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 15:01
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SynAct Pharma AB is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrik LingDNB Markets
Carl RamaniusRedeye